Symbols and abbreviations |
|
xv | |
How to use this book |
|
xxi | |
Introductory sections |
|
1 | (30) |
|
|
|
|
2 | (3) |
|
|
5 | (1) |
|
Generic drugs and biosimilars |
|
|
6 | (1) |
|
|
7 | (2) |
|
Off-licence drugs Cautionary and advisory labels |
|
|
9 | (1) |
|
|
|
The World Health Organization (WHO) essential medicines list |
|
|
10 | (1) |
|
Compliance, adherence, and concordance |
|
|
11 | (1) |
|
|
12 | (2) |
|
Dose-response curves (concentration-effect curves) |
|
|
14 | (1) |
|
|
15 | (1) |
|
|
16 | (2) |
|
|
18 | (2) |
|
|
20 | (1) |
|
Changing the doses of drugs |
|
|
21 | (1) |
|
|
22 | (1) |
|
|
22 | (1) |
|
An approach to rational prescribing |
|
|
23 | (1) |
|
|
24 | (2) |
|
|
26 | (2) |
|
Drug therapy and breastfeeding |
|
|
28 | (2) |
|
|
30 | (1) |
1 Gastrointestinal system |
|
31 | (50) |
|
|
|
Histamine H., receptor antagonists BNF 1.3.1 |
|
|
32 | (2) |
|
Proton pump inhibitors (PPIs) BNF 1.3.5 |
|
|
34 | (4) |
|
Misoprostol BNF 1.3.4, 10.1.1 |
|
|
38 | (4) |
|
Drugs affecting gastrointestinal motility |
|
|
|
|
42 | (2) |
|
Co-phenotrope (Lomotil®) BNF 1.4.2 |
|
|
44 | (2) |
|
Loperamide (Imodium®) BNF 1.4.2 |
|
|
46 | (2) |
|
Inflammatory Bowel Disease |
|
|
|
Mesalazine and related compounds (aminosalicylates) BNF 1.5 |
|
|
48 | (4) |
|
Su ifasalazine BNF 1.5.1 and 10.13 |
|
|
52 | (2) |
|
Liver, biliary system, and lipids |
|
|
|
|
54 | (2) |
|
HMG CoA reductase inhibitors ('statins') BNF 2.12 |
|
|
56 | (4) |
|
|
60 | (2) |
|
|
62 | (2) |
|
|
|
|
64 | (2) |
|
|
|
|
66 | (4) |
|
Prochlorperazine (Stemetir) BNF 4.6 |
|
|
70 | (6) |
|
|
76 | (2) |
|
Serotonin 5-HT3 receptor antagonists BNF 4.6 |
|
|
78 | (3) |
2 Cardiovascular system |
|
81 | (160) |
|
A pharmacological approach to the treatment of arrhythrnias BNF 2.3.1 |
|
|
84 | (2) |
|
|
|
|
86 | (4) |
|
|
90 | (4) |
|
Cardiac glycosides (digitalis) BNF 2.1.1, 2.3.1. and 2.5.5 |
|
|
94 | (6) |
|
|
100 | (4) |
|
Amiodarone BNF 2,3.2 and 2.7.3 |
|
|
104 | (6) |
|
Anticoagulants, antiplatelet drugs, and fibrinolytic drugs |
|
|
|
Heparins (unfractionated and low molecular weight) BNF 2.8.1 |
|
|
110 | (8) |
|
Direct thrombin inhibitors BNF 2.8.2 |
|
|
118 | (2) |
|
Fondaparinux sodium BNF 2.8.1 |
|
|
120 | (4) |
|
|
124 | (8) |
|
Acetylsalicylic acid (aspirin) BNF 2.9 and 4.7.1 |
|
|
132 | (6) |
|
|
138 | (4) |
|
|
142 | (2) |
|
Glycoprotein Ilbillia antagonists BNF 2.9 |
|
|
144 | (2) |
|
Fibrinolytic drugs BNF 2.10.2 and 13.11.7 |
|
|
146 | (4) |
|
|
|
Pharmacology of drugs used to treat acute coronary syndromes, including myocardial infarction BNF 2.10 |
|
|
150 | (1) |
|
Pharmacology of drugs used to treat heart failure |
|
|
151 | (1) |
|
|
152 | (4) |
|
|
156 | (2) |
|
Beta-adrenoceptor antagonists ('beta-blockers') BNF 2.4, 2.5.5, 6.2.2, 4.7.4, 11.6 |
|
|
158 | (8) |
|
Angiotensin converting enzyme inhibitors (ACE inhibitors) BNF 2.5.5.1 |
|
|
166 | (6) |
|
Angiotensin receptor antagonistsiblockers (ARBs) BNF 2.5.5.2 |
|
|
172 | (4) |
|
|
|
An approach to the treatment of hypertension BNF 2.5 |
|
|
176 | (2) |
|
Methyldopa (alpha-methyldopa) BNF 2.5.2 |
|
|
178 | (2) |
|
|
|
Calcium channel blockers (see also individual sections) BNF 2.6.2 |
|
|
180 | (2) |
|
Dihydropyridines (nifedipine-like) BNF 2.6.2 |
|
|
182 | (4) |
|
Benzothiazepines (diltiazem) BNF 2.6.2 and 2.3.2 |
|
|
186 | (2) |
|
Phenylalkylamines (verapamil) BNF 2.6.2 and 2.3.2 |
|
|
188 | (2) |
|
|
|
Crystalloid solutions for intravenous infusion BNF 9.7 |
|
|
190 | (4) |
|
Colloid solutions for intravenous infusion BNF 9.2 |
|
|
194 | (3) |
|
|
|
Sites of action of diuretics BNF 2.2 |
|
|
197 | (1) |
|
Treatment of pulmonary oedema BNF 2.2 |
|
|
198 | (2) |
|
Loop diuretics BNF 2.2.2 and 2.2.4 |
|
|
200 | (6) |
|
Thiazide and thiazide-like diuretics BNF 2.7.1, 2.5.5, and 6.5.2 |
|
|
206 | (4) |
|
Potassium-sparing diuretics (amiloride and triamterene) BNF 2,2.3 and 2.2.4 |
|
|
210 | (4) |
|
Spironolactone and eplerenone BNF 2.2.3, 2.2.4, and 2.5.5 |
|
|
214 | (4) |
|
|
|
Adrenoceptor agonists (sympathomimetics) BNF 2.7 |
|
|
218 | (8) |
|
|
|
Muscarinic acetylcholine receptor antagonists (atropine and related compounds) BNF 35.1.3, 4.6, 4.9.2, 7.4.2, and 11.5 |
|
|
226 | (6) |
|
Endothelin receptor antagonists |
|
|
|
Endothelin receptor antagonists BNF 2.5.1 |
|
|
232 | (4) |
|
Drugs for erectile dysfunction |
|
|
|
Phosphodiesterase type V inhibitors BNF 7.4.5 |
|
|
236 | (5) |
3 Respiratory system |
|
241 | (38) |
|
|
|
|
242 | (4) |
|
Asthma and chronic obstructive pulmonary disease (COPD) |
|
|
|
Pharmacology of drugs used to treat asthma BNF 3.1 |
|
|
246 | (2) |
|
An approach to the treatment of chronic obstructive pulmonary disease (COPD) BNF 3.2 |
|
|
248 | (2) |
|
Short-acting 132 adrenoceptor agonists BNF 3.1.1.1 and 7.1.3 |
|
|
250 | (4) |
|
Long-acting 132 adrenoceptor agonists BNF 3.1.1.1 |
|
|
254 | (4) |
|
Bronchodilatory muscarinic receptor antagonists BNF 3.1.2 |
|
|
258 | (4) |
|
Leukotriene receptor antagonists BNF 3.3.2 |
|
|
262 | (2) |
|
Cromones BNF 3.3.1.1.5, and 11.4.2 |
|
|
264 | (2) |
|
Xanthine derivatives BNF,3.1.3 |
|
|
266 | (6) |
|
|
|
|
272 | (2) |
|
|
|
|
274 | (2) |
|
Bupropion (amfebutamone) BNF 4.10 |
|
|
276 | (3) |
4 Central nervous system |
|
279 | (94) |
|
|
|
Carbamazepine BNF 4.8.1, 4.7.3, 6.5.2, 6.1.5 |
|
|
280 | (8) |
|
Phenytoin BNF 4.8.1, 4.8.2 and 4.7.3 |
|
|
288 | (6) |
|
Sodium valproate BNF 4.8.1 |
|
|
294 | (4) |
|
|
298 | (4) |
|
Other antiepileptic drugs BNF 4.8.1 |
|
|
302 | (2) |
|
Barbiturates BNF 4.1.3. 4.8.1 and 15.1.1 |
|
|
304 | (4) |
|
Anxiolytics and hypnotics |
|
|
|
Benzediazepines BNF 4.1.1, 4.1.2 and 4.8.2 |
|
|
308 | (8) |
|
Renzodiazepine-like hypnotics BNF 4.1.1 |
|
|
316 | (2) |
|
|
|
Tricyclic antidepressants BNF 4.3.1, 6.1.5, 4.7.4.2 and 7.4.2 |
|
|
318 | (6) |
|
Selective serotonin reuptake inhibitors (SSRIs) BNF 4.3.3 |
|
|
324 | (6) |
|
|
330 | (2) |
|
Monoamine oxidase inhibitors (MAOIs) ar4F 4.3.2, 4.9.1 |
|
|
332 | (4) |
|
Psychoses and bipolar disorder |
|
|
|
Antipsychatic/neuroleptic drugs BNF 4,2 |
|
|
336 | (6) |
|
Atypical antipsychotic drugs BNF 4.2.1 |
|
|
342 | (6) |
|
|
348 | (4) |
|
|
|
Pharmacology of drugs used to treat Parkinson's disease BNF 4.9 |
|
|
352 | (2) |
|
Levodopa (L-dopa) BNF 4.9.1 |
|
|
354 | (4) |
|
Dopamine receptor agonists BNF 4.9.1 and 6.7.1 |
|
|
358 | (4) |
|
Entacapone BNF 4.9.1 and 6.7.1 |
|
|
362 | (2) |
|
|
|
Acetylcholinesterase inhibitors BNF 10.2.1, 4.11, 15.1.6, 7.4,1 and 1.6.2 |
|
|
364 | (4) |
|
|
|
Serotonin 5-HT1 receptor agonists ('triptans') BNF 4.7.4 |
|
|
368 | (5) |
5 Infections |
|
373 | (78) |
|
|
|
|
374 | (4) |
|
|
378 | (2) |
|
Cephalosporins and cephamycins BNF 5.1.2 |
|
|
380 | (4) |
|
Glycopeptide antibiotics BNF 5.1.7 |
|
|
384 | (4) |
|
Tetracyclines BNF 5.1.3 and 13.6.2 |
|
|
388 | (6) |
|
Aminoglycoside antibiotics BNF 5.1.4 |
|
|
394 | (4) |
|
Macrolide antibiotics BNF 5.1.5 |
|
|
398 | (6) |
|
Sulfonamides and trimethoprim (including co-trimoxazole) BNF 5.12 and 13.10.1.1 |
|
|
404 | (6) |
|
Metronidazole and tinidazole BNF 5.1.11 |
|
|
410 | (4) |
|
Quinolone antibiotics BNF 5.1.12 |
|
|
414 | (4) |
|
|
|
Antituberculosis drugs BNF 5.1.9 |
|
|
418 | (4) |
|
|
|
Antiviral guanine derivatives BNF 5.3, 11.3.3, and 13.10.3 |
|
|
422 | (6) |
|
Drugs used to treat human immunodeficiency virus (HIV) infection BNF 5.3 |
|
|
428 | (8) |
|
|
|
Imidazole and triazole antifungal drugs BNF 5.2, 7.2.2, 12.3.2, and 13.10.2 |
|
|
436 | (4) |
|
Polyene antifungal drugs BNF 5.2, 7.2.2, 12.3.2, and 13.10.2 |
|
|
440 | (4) |
|
|
|
Antimalarial drugs BNF 5.4.1 |
|
|
444 | (7) |
6 Endocrine system; obstetrics and gynaecology |
|
451 | (84) |
|
|
|
|
452 | (10) |
|
|
462 | (2) |
|
Sulfonylureas BNF 6.1.2,1 |
|
|
464 | (4) |
|
|
468 | (2) |
|
Biguanides (metformin) BNF 6.1.2.2 |
|
|
470 | (4) |
|
Thiazolidinediones ('glitazones') BNF 6.1,2,3 |
|
|
474 | (4) |
|
|
|
Thyroid hormones BNF 6.2.1 |
|
|
478 | (4) |
|
|
482 | (4) |
|
|
|
|
486 | (2) |
|
|
488 | (8) |
|
|
|
Corticotrophins BNF 6.5.1 |
|
|
496 | (2) |
|
|
|
Oestrogens and hormone replacement therapy (HRT) BNF 6.4.1, 7.2.1 and 8.3.1 |
|
|
498 | (4) |
|
Progestogens BNF 6.4.1.2, 8.3.2, and 7.3 |
|
|
502 | (2) |
|
Oral contraceptives BNF 7.3 |
|
|
504 | (4) |
|
Notes on contraceptive devices BNF 7.3.2.3, 7.3.3, and 7.14 |
|
|
508 | (2) |
|
Gonadorelln analogues BNF 6.7.2 and 8.3.4.1 & 2 |
|
|
510 | (2) |
|
Androgens and anabolic steroids BNF 6.4,2 and 6.4.3 |
|
|
512 | (4) |
|
Antiandrogens BNF 8.3.4.2, 6.4,2 and 13.6.2 |
|
|
516 | (4) |
|
Selective oestrogen receptor modulators (SERMs) BNF 8.3.4.1 and 6.5.1 |
|
|
520 | (4) |
|
Aromatase inhibitors BNF 8.3.4.1 |
|
|
524 | (2) |
|
|
|
Prostaglandins BNF 7.1.1,7.4.5, and 11.6 |
|
|
526 | (4) |
|
|
530 | (2) |
|
Somatostatin and analogues |
|
|
|
Somatostatin and analogues BNF 8.3.4.3 |
|
|
532 | (3) |
7 Kidneys and the urinary tract |
|
535 | (18) |
|
|
|
Renal insufficiency BNF 7.4.3 |
|
|
536 | (2) |
|
Drug-induced renal damage BNF 7.4,3 |
|
|
538 | (2) |
|
Drugs and renal stones BNF 7.43 |
|
|
540 | (2) |
|
Drugs and renal replacement therapy (dialysis or filtration) BNF 7.4,3 |
|
|
542 | (2) |
|
Drugs used in the management of chronic renal insufficiency BNF 7.4.3 |
|
|
544 | (2) |
|
|
|
Alpha-adrenoceptor antagonists (alpha-blockers) BNF 7.4.1 and 2.5.4 |
|
|
546 | (4) |
|
Antidiuretic hormone (ADH, vasopressin) and analogues SNF 7.4.1 and 7.4.2 |
|
|
550 | (3) |
8 Malignant disease and immunosuppression |
|
553 | (44) |
|
Drugs used to treat cancer |
|
|
|
Drugs used to treat cancer BNF 8.1 |
|
|
554 | (2) |
|
Adverse effects of cytotoxic chemotherapy BNF 8.1 |
|
|
556 | (2) |
|
|
558 | (2) |
|
Cyclophosphamide BNF 8.1.1 |
|
|
560 | (2) |
|
Cytotoxic antibiotics BNF 8.1.2 |
|
|
562 | (4) |
|
Antimetabolite drugs BNF 8.1.3, 10.1.3, and 13.5.2 |
|
|
566 | (4) |
|
Methotrexate BNF 8:1.3, 10.1.3, and 13.5.2 |
|
|
570 | (4) |
|
Vinca alkaloids BNF 8.1.4 |
|
|
574 | (2) |
|
Platinum compounds BNF 8.1.5 |
|
|
576 | (2) |
|
|
578 | (2) |
|
Cytotoxic monoclonal antibodies BNF 8.1.5 and 8.2.3 |
|
|
580 | (4) |
|
|
|
Azathioprine and mercaptopurine BNF 8.2, 8.1.3, 1.5. 10.1.3, and 10.2.1 |
|
|
584 | (4) |
|
Mycophenolate mofetit and mycophenolic acid BNF 8.2.1 |
|
|
588 | (4) |
|
Ciclosporin, tacrolimus, and sirolimus BNF 8.2.2 and 13.5.3 |
|
|
592 | (5) |
9 Nutrition and blood |
|
597 | (42) |
|
Blood, blood products, and anaemia |
|
|
|
Drugs and anaemia BNF 9.1 |
|
|
598 | (2) |
|
|
600 | (4) |
|
Factor VIII and related products BNF 2.11 |
|
|
604 | (4) |
|
Erythropoietin and analogues BNF 9.1.3 |
|
|
608 | (4) |
|
Colony stimulating factors BNF 9.1.6 |
|
|
612 | (2) |
|
|
614 | (4) |
|
Folic acid and folinic acid BNF 9.1.2 and 8.1 |
|
|
618 | (2) |
|
|
620 | (2) |
|
Desferrioxamine (deferoxamine) BNF 9.1.3 |
|
|
622 | (2) |
|
|
|
Calcium salts ONE 9.5.1.1 and 9.6.4 |
|
|
624 | (2) |
|
Magnesium sulphate BNF 9.5.1.3 |
|
|
626 | (2) |
|
Potassium chloride BNF 9.2.1.1 |
|
|
628 | (4) |
|
|
|
Vitamin D analogues ONE 9.6.4 and 13.5.2 |
|
|
632 | (4) |
|
|
636 | (3) |
10 Musculoskeletal and joints |
|
639 | (38) |
|
|
|
|
640 | (2) |
|
Allopurinol ONE 10.1.4 and 8.1 |
|
|
642 | (2) |
|
Rheumatoid arthritis (disease-modifying drugs) |
|
|
|
Rheumatoid arthritis (disease-modifying drugs) BNF 10.1 |
|
|
644 | (2) |
|
Chloroquine and hydroxychloroquine BNF 5.4.1 and 10.1.3 |
|
|
646 | (4) |
|
|
650 | (2) |
|
|
652 | (2) |
|
Tumour necrosis factor (TNF) blocking drugs BNF 10.1.3 and 1.5.3 |
|
|
654 | (4) |
|
|
|
Calcitonin BNF 6.6.1 and 9.5.1.2 |
|
|
658 | (2) |
|
Bisphosphonates BNF 6.6.2 and 9.5.1.2 |
|
|
660 | (6) |
|
|
|
|
666 | (2) |
|
Dantrolene BNF 15.1.8 and 10.2.2 |
|
|
668 | (2) |
|
Neuromuscular blocking drugs BNF 15.1.5 |
|
|
670 | (4) |
|
Botulinum toxin BNF 4.9.3 |
|
|
674 | (3) |
11 Eye |
|
677 | (10) |
|
|
|
Acetylcholine receptor agonists BNF 11.6, 12.3.5, and 7.4.1 |
|
|
678 | (2) |
|
Carbonic anhydrase inhibitors BNF 11.6, 4.8, and 2.2.7 |
|
|
680 | (4) |
|
Drugs for macular degeneration BNF 11.8.2 |
|
|
684 | (3) |
12 Skin |
|
687 | (8) |
|
|
|
Antihistamines BNF 3.4.1, 13.5.1, 11.4.2, 4.6, and 12.2.1 |
|
|
688 | (4) |
|
|
|
Retinoids BNF 13.6.1, 8.15, 13.5.2 and 13.8.1 |
|
|
692 | (3) |
13 Poisoning |
|
695 | (24) |
|
|
|
An approach to the poisoned patient |
|
|
696 | (2) |
|
|
698 | (2) |
|
|
|
Acetylcysteine (Parvolex) |
|
|
700 | (4) |
|
Opioid antagonists BNF 15.1.7 |
|
|
704 | (6) |
|
|
710 | (2) |
|
Penicillamine BNF 9.8.1 and 10.1.3 |
|
|
712 | (4) |
|
|
|
|
716 | (3) |
14 Immunological products and vaccines |
|
719 | (16) |
|
|
|
Immunoglobulins BNF 14.5 and 14.2 |
|
|
720 | (4) |
|
|
|
Interferons BNF 8.2.4, 5.3, and 14.5 |
|
|
724 | (4) |
|
|
|
|
728 | (4) |
|
UK immunization schedule BNF 14.1 and 14.4 |
|
|
732 | (3) |
15 Relief of pain and anaesthetic drugs |
|
735 | (44) |
|
|
|
|
736 | (2) |
|
Paracetamol (acetaminophen) BNF 4.7.1 |
|
|
738 | (4) |
|
Non-steroidal anti-inflammatory drugs (NSAIDS) BNF 10.1.1 and 15.1.4.2 |
|
|
742 | (6) |
|
Codeine phosphate and dihydrocodeine BNF 4.7.1, 4.7.2, 1.4.2 and 3.9.1 |
|
|
748 | (4) |
|
Opiates and non-opiate narcotic analgesics BNF 4.7.2 and 15,1.4.3 |
|
|
752 | (8) |
|
Treatment of neuropathic pain BNF 4.7.3. |
|
|
760 | (2) |
|
Pregabalin BNF 4.7.3 and 4.8.1 |
|
|
762 | (2) |
|
Gabapentin BNF 4.7.3, 4.8.1 and 6.1.5 |
|
|
764 | (2) |
|
Capsaicin BNF 10.3.2, 4.7.3, and 6.1.5 |
|
|
766 | (2) |
|
Lidocaine (lignocaine) BNF 2.3.2 and 15.2 |
|
|
768 | (4) |
|
|
772 | (4) |
|
Volatile anaesthetics BNF 15.1.2 |
|
|
776 | (3) |
Drug index |
|
779 | (10) |
Subject index |
|
789 | |